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Background: Chronic kidney disease (CKD) involves a progressive, irreversible loss of kidney function. While early-
stage CKD patients may show changes in pulmonary function and lowered exercise tolerance, the role of the
estimated glomerular filtration rate (eGFR) in these patterns remains unknown. The aim of this study was to
investigated pulmonary function and exercise tolerance in pre-dialytic CKD patients.
Methods: A cross-sectional study was carried out with 38 adult volunteers divided into a control group (CG),
consisting of 9 healthy adults, and 29 pre-dialytic CKD patients in stages 3 (G3), 4 (G4), and 5 (G5). All participants
underwent spirometric and manovacuometric tests, a cardiopulmonary exercise test (CPET), a 6-minute walk test
(6MWT), and laboratory tests.
Results: The significant differences was observed in maximal exercise tolerance, measured as peak oxygen
consumption percentage (VO2peak) (mL/kg/min) (CG = 28.9 ± 7.8, G3 = 23.3 ± 5.6, G4 = 21.4 ± 5.2, G5 = 20.2 ± 6.9;
p = 0.03), and submaximal exercise tolerance, measured by 6MWT (m) (CG = 627.6 ± 37.8, G3 = 577.4 ± 66.1,
G4 = 542.7 ± 57.3, G5 = 531.5 ± 84.2, p = 0.01). The eGFR was associated with pulmonary function-forced expiratory
volume in the first second percentage (FEV1) (%) (r = 0.34, p = 0.02) and maximum inspiratory pressure (PImax)
(r = 0.41, p = 0.02) - and exercise tolerance - VO2peak (mL/kg/min) (r = 0.43, p = 0.01) and 6MWT distance (m)
(r = 0.55, p < 0.01).
Conclusion: Pre-dialytic CKD patients showed lower maximal and submaximal exercise tolerances than healthy
individuals.
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Chronic kidney disease (CKD) is a worldwide public
health problem. In Brazil, there are an estimated 2.9 mil-
lion patients with an estimated glomerular filtration rate
(eGFR) lower than 45 mL/min/1.73 m2, which classifies
them as CKD stage 3B, 4 or 5 [1]. CKD often results in
complications and comorbidities which compromise the* Correspondence: ruiterfaria@gmail.com
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reproduction in any medium, provided the orfunction of various organs and may lead to premature
mortality [2].
Respiratory problems are common in patients undergo-
ing dialysis treatment, and these arise from a variety of
factors, such as interstitial and alveolar edema, pleural ef-
fusion due to volume overload or increased capillary per-
meability [3], pulmonary hypertension [4], haemosiderosis
[5], and weakness of the pulmonary muscles [6]. Haemo-
dialysis patients present increased interstitial fluid volume,
weakened muscles, and decreased diffusion capacity [7].
Peritoneal dialysis causes increased intra-abdominal pres-
sure, which results in changes in respiratory mechanicsd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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therapy over 36 months showed an association between
inflammation and worsened respiratory function, as well
as a higher relative risk of mortality among patients with
the worst forced vital capacity [9]. In fact, most of the
available literature evaluated the pulmonary function in
dialysis patients. However, the relation between the de-
crease in the eGFR and the respiratory function in pre-
dialytic CKD patients remains unclear.
Various studies have shown that cardiovascular dis-
eases, peripheral muscle dysfunction, anaemia and sed-
entary lifestyle result in a reduction in exercise tolerance
and quality of life and are associated with higher mortal-
ity in CKD [10-13]. Renal transplant patients showed
higher exercise tolerance than haemodialysis patients,
which was attributed to improvement in kidney function
associated with removal of uremic toxins [14]. Despite
their potential relevance in CKD, exercise tolerance and
pulmonary function have been little studied in pre-
dialytic CKD patients [15] The aim of this study, there-
fore, was to evaluate the respiratory function and the
exercise tolerance of pre-dialytic CKD patients in stages
3, 4, and 5.
Methods
A cross-sectional study was performed from June through
November 2011 as part of the Program of Secondary Pre-
vention of Kidney Disease at the Interdisciplinary Nucleus
of Studies, Research and Treatment in Nephrology of the
Federal University of Juiz de Fora, Minas Gerais, Brazil.
The inclusion criteria were adult pre-dialytic CKD pa-
tients in stages 3, 4 and 5 based on the CKD staging
proposed by the Kidney Disease Outcomes Quality Ini-
tiative [16]. The control group (CG) consisted of healthy
individuals recruited from among the programme
staff or their families. The study was approved by the
Research Ethics Committee of the Federal University of
Juiz de Fora and participants signed a consent form.
The exclusion criteria were as follows: patients older
than 65 years; prior diagnoses of pulmonary diseases;
current smokers, past smokers who quit less than 10
years before the study, or patients with a history of
smoking more than 20 packs per year; cognitive or mus-
culoskeletal conditions that would compromise test per-
formance; unstable angina; an active infection in the
previous 3 months; uncontrolled hypertension (systolic
blood pressure ≥200 mmHg and/or diastolic blood pres-
sure ≥ 120 mmHg); and the use of medication that could
affect respiratory musculature function (e.g. steroids or
cyclosporine).
Participants first underwent medical (anamnesis and
physical examination) and physical (musculoskeletal)
assessment to identify any clinical conditions that could
limit their participation in the study. Immediatelyafterwards, blood samples were collected and tested for
creatinine (mg/dL), potassium (mEq/L), haemoglobin
(g/dL), calcium (mg/dL), phosphorus (mg/dL), albumin
(g/dL), alkaline phosphatase (U/L), parathyroid hor-
mone intact molecule (PTH-i) (pg/mL), total cholesterol
(mg/dL), triglycerides (mg/dL), and venous gasometry.
The eGRF was calculated from serum creatinine using
Modification of Diet in Renal Disease equation [16].
The pulmonary function tests and functional capacity
tests are exercise-dependent tests, and were therefore
performed in different days so that the results would not
be compromised because of fatigue in these tests. Evalu-
ations were performed at 3 different visits. At first, the
blood sample test and the 6-minute walk test (6MWT)
were performed. In the second visit, the spirometry and
the manovacuometry were performed with a interval of
1 hour between these tests. Cardiopulmonary exercise
test (CPET) was performed only in the third visit. The
visits were carried out between 15 to 30 days.
Assessment of respiratory function
Spirometry
Patients underwent spirometry tests with a KoKo® appar-
atus (Koko Spirometer, Louisville, USA), following the
recommendations of the Brazilian Society of Thoracic
Medicine for tests of pulmonary function [17]. Before each
test, the apparatus was calibrated with a 1 L syringe
(Vitalograph Precision Syringe, Vitalograph, England), such
that variability after 3 tests was < 3% (3 L). The forced ex-
piratory volume in 1 second (FEV1), forced vital capacity
(FVC), and the ratio FEV1/FVC were measured. From at
least 2 sessions (with up to 8 attempts) the 2 highest values
of FVC and FEV that differed by less than 0.15 L and peak
expiratory flow (PEF) less than 10% or 0.5 L (whichever
was greater) were selected. These values were standardised
to percentages of expected values (%) based on data from
the broader Brazilian population [18].
Manovacuometry
A Ger-ar® Classe B (São Paulo, Brazil) calibrated analog
manovacuometer with an operational interval of ±
150 cmH2O was used to assess respiratory muscle
strength via exercises to measure maximum inspiratory
pressure (PImax) and maximum expiratory pressure
(PEmax). Subjects were tested in a seated position, wear-
ing a nose clip. Three measurements were taken with in-
tervals of 2 seconds during which values were recorded.
To compare results between groups, measured values
converted to the expected percentage (%) were used for
the broader Brazilian population [19].
Assessment of exercise tolerance
A CPET and a 6MWT were used to assess maximal and
submaximal exercise tolerances, respectively.
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The CPET was carried out according to the recommen-
dations of the American Thoracic Society [20] on an
ergometric treadmill (Inbrasport®, Porto Alegre, Brazil)
equipped with a computerised system for an exercise
test (Ergo-PC Elite, Micromed Biotecnologia®, Brasília,
Brazil). To analyse exhaled gases, patients wore a gas
mask connected to a gas analyser (VO2000, Inbrasport®,
Porto Alegre, Brazil). During the test, the electrocardio-
gram and heart rate were monitored continuously via 3
cutaneous electrodes placed to record the CM5 lead. In
addition, blood pressure was monitored using the aus-
cultatory method every 2 minutes. The ramp protocol
was used, with constantly increasing incline which varied
depending on the tolerance of each individual, until
physical exhaustion was evident, despite being encour-
aged by the investigators, or until another criterion to
interrupt the test was recorded. Peak oxygen consumption
(VO2peak) was defined as the highest O2 consumption
reached during the test. The values considered normal for
VO2peak vary according to sex and age and are calculated
using mathematical equations of the American College of
Sports Medicine [21]. The anaerobic threshold (AT) was
estimated using the V-slope method and ventilatory equiv-
alents [22,23].
Six-minute walk test (6MWT)
The 6MWT was carried out according to the recom-
mendations of the American Thoracic Society [24].Figure 1 Flow diagram of selection process of study subjects.Individuals were instructed to walk as fast as possible
during the 6 minutes on a flat 30-m track, and the dis-
tance walked was recorded in meters. Patients were
allowed to stop and rest during the test but were
instructed to resume walking as soon as they felt able to
do so. The two tests were completed on the same day,
with an interval of 30 minutes between each, and the
farthest distance each patient walked was used to calcu-
late the percentage relative to the predicted distance
[25]. At the end of the test, perceived levels of effort
were obtained using the modified Borg scale [26].
Statistical analysis
The descriptive analysis and the normality test (Shapiro
Wilk) were performed. The descriptive statistics was
used to explore patterns in the demographic, clinical,
and laboratory variables, and in the variables that assess
exercise tolerance and respiratory function. The data
were expressed as means and standard deviations or
percentages, depending on the distribution. Initially the
group was divided in patients and controls and Student’s
T test and Chi Squared were utilized for comparison. Sub-
sequently, patients were divided into groups correspond-
ing to CKD stages 3, 4 and 5 and compared with the
control group. Among group comparisons were carried
out with normally distributed data using ANOVA. For
non-normally distributed data chi-squared test was used.
The correlations between variables were tested with
Pearson or Spearman’s correlation tests, based on the
Table 1 Descriptive analysis of clinical and laboratory data
Variables Control Stage 3 Stage 4 Stage 5 P
(CG = 9) (G3 = 10) (G$ = 10) (G5 = 9)
Age (years) 51.5 ± 7.5 56.8 ± 5.8 52.3 ± 8.5 56.3 ± 9.0 0.351
Sex (F/M) 4/5 5/5 6/4 5/4 0.914
BMI (kg/m2) 27.2 ±4.6 29.5 ± 5.7 26.3 ± 6.5 27.9 ± 5.6 0.655
CKD Etiology:
Hypertensive Nx - 5 3 2 <0.001*
Diabetic Nx - 1 2 2
CGN - 1 2 3
Others - 3 3 2
Comorbidities:
H - 10 9 9 <0.001*
DM - 2 4 2 <0.001*
Dyslipidemia - 6 6 8 <0.001*
eGFR (mL/min/1.73m2) 77.6 ± 9.8b,c,d 43.8 ± 8.7a,c,d 21.3 ± 4.2a,b,d 12.7 ± 3.7a,b,c <0.001*
Creatinine (mg/dL) 0.9 ± 0.1b,c,d 1.5 ± 0.2a,c,d 2.7 ± 0.6a,b,d 4.4 ± 1.3a,b,c <0.001*
Potassium (meq/L) 4.6 ± 0.4d 4.4 ± 0.5d 4.7 ± 0.9 5.4 ± 0.9 0.049
Calcium (mg/dL) 10.0 ± 0.6 9.9 ± 1.0 9.9 ± 0.7 10.2 ± 0.6 0.852
Phosphorus (mg/dL) 4.8 ± 2.2 3.6 ± 0.6 4.1 ± 0.8 4.9 ± 0.6 0.081
Alkaline phosphatase (U/L) 155.2 ± 41.1d 193.8 ± 38.3d 220.1 ± 51.1d 305.5 ± 144.7 0.014
PTHi (pg/mL) 71.2 ± 29.8d 77.0 ± 24.9d 114.2 ± 52.2d 337.2 ± 283.0 0.004
Hemoglobin (g/dL) 15.0 ± 1.8c,d 13.7 ± 1.4c 12.3 ± 1.3 12.3 ± 1.6 0.003
Albumin (g/dL) 3.9 ± 0.1 4.2 ± 0.3 3.6 ± 0.5 4.2 ± 0.5 0.102
Total cholesterol (mg/dL) 201.6 ± 41.5 207.8 ± 43.5 190.6 ± 40.7 215.4 ± 59.3 0.698
Triglycerides (mg/dL) 106.5 ± 45.9 147.6 ± 81.8 179.1 ± 120.0 252.1 ± 221.3 0.163
HCO3 (mmol/L) 28.0 ± 0.8
c,d 27.3 ± 2.5c,d 23.7 ± 3.8 22.0 ± 4.5 0.003
<0.001* = P-value for comparison between the control Group and the CKD groups (Stage 3,4 and 5); BMI Body Mass Index, Nx Nephropathy, CKD Chronic kidney
disease, CGN Chronic glomerulonephritis, H Hypertension, DM Diabetes Mellitus, eGFR estimated Glomerular Filtration Rate, PTHi Parathyriod Hormone Intact
Molecule, HCO3 Bicarbonate.
Post hoe analysis: a = differs from CG at p<0.05; c = differs from G4 at p<0.05; d = differs from G5 at p<0.05.
Table 2 Assessment of pulmonary function (spirometry and manovacuometry)
Variables Control Stage 3 Stage 4 Stage 5 P
(CG = 9) (G3 = 10) (G4 = 10) (G5 = 9)
Spirometry
FVC (%) 118.0 ± 136.7 101.7 ± 20.2 98.3 ± 15.1 97.3 ± 21.1 0.115
FEV, (%) 111.0 ± 10.4 100.4 ± 18.4 95.0 ± 13.1 92.1 ± 19.1 0.126
FEV,/FVC (%) 94.9 ± 4.5 99.3 ± 7.8 97.5 = 5.3 95.0 ± 4.0 0.333
Manovacuometry
PImax (%) 93.3 ± 14.3 63.2 ± 27.1 62.0 = 12.5 69.9 ± 29.0 0.061
PEmax (%) 108.4 ± 16.5 94.1 ± 21.9 84.4 = 16.4 89.6 ± 25.6 0.192
FVC Forced Vital Capacity, FEV1 Forced Expiratory Volume in the first second of forceful exhalation, PImax Maximum Inspiratory Pressure, PEmax Maximum
Expiratory Pressure.
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Table 3 Assessment of exercise tolerance (cardiopulmonary exercise test and six-minute walk test)
Variables Control Stage 3 Stage 4 Stage 5 P
(CG = 9) (G3 = 10) (G4 = 10) (G5 = 9)
Cardiopulmonary test
RPmax (W/kg) 4.9 ± 1.3 3.7 ± 0.9a 3.0 ± 1.2a 3.2 ± 1.0a 0.007
VO2peak (mL/kg/min) 28.9 ± 7.8 23.3 ± 5.6 21.4 ± 5.2
a 20.2 ± 6.9a 0.033
VO2peak (%) 85.4 ± 18.2 75.8 ± 18.3 65.9 ± 16.0
a 63.4 ± 16.0a 0.038
VO2AT (mL/kg/min) 20.5 ± 4.1 15.7 ± 3.5
a 16.6 ± 3.8a 13.6 ± 3.8a 0.005
VEmax (l/min) 68.2 ± 20.3 60.8 ± 20 49.7 ± 20 56.9 ± 28.9 0.356
HRmax (bpm) 165 ± 14 146 ± 16a 139 ± 23a 129 ± 18a 0.003
HRmax (%) 97.9 ± 34.6 90.0 ± 11.1 82.8 ± 11.5a 79.3 ± 9.9a 0.003
SBPmax (mmHg) 197.5 ± 34.6 202.6 ± 25.8 204.2 ± 35.5 201.7 ± 34.3 0.976
DPBmax (mmHg) 89.7 ± 7.5 97.6 ± 9.2 101.8 ± 18.7 98.8 ± 9.6 0.203
6MWT
Distance (m) 627.6 ± 37.8 577.4 ± 66.1 542 ± 57.3a 531.5 ± 84.2a 0.012
% Predicted (%) 90.5 ± 7.6 93.9 ± 7.5 83.4 ± 9.5b 83.0 ± 8.9b 0.017
RPmax Maximum Relative Power, VO2peak Peak Oxygen Consumption, VO2AT Oxygen Consumption at Anaerobic Threshold, VE Minute Ventalation, HRmax
Maximum Heart Rate, SBPmax Maximum Systolic Blood Pressure, DBPmax Maximum Diastolic Blood Pressure.
Post hoc analysis: a = differs from CG at p<0.05; b = differs from G3 at p<0.05.
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0.05 and a confidence interval of 95% were used. Analysis
was carried out using SPSS 13.0 software.
Results
Of the 348 pre-dialytic CKD patients assessed for eligi-
bility, 317 were excluded from the study for the reasons
shown in Figure 1. Twenty-nine of the 31 patients who
fulfilled the criteria for inclusion in the study agreed to
participate: 10 in CKD stage 3 (G3), 10 in stage 4 (G4)
and 9 in stage 5 (G5). The control group consisted of 9
healthy individuals.
The mean time since diagnosis time was 4.47 ± 2.67
years (median 4 years). No statistical differences among
groups in age, sex or body mass index were observed.
The most prevalent cause of CKD was hypertensive ne-
phropathy (34.4%), followed by chronic glomeruloneph-
ritis (20.6%) and diabetic nephropathy (17.2%). The mostTable 4 Correlations between the estimated glomerular
filtration rate, spirometric variables, and exercise
tolerance variables
Variables Estimated glomerular filtration rate
(mL/min/1.73 m2)
r p
FVC (%) 0.348 0.041
FEV, (%) 0.349 0.020
RPmax (W/kg) 0.536 0.001
VO2peak (mL/kg/min) 0.430 0.008
VO2AT (mL/kg/min) 0.481 0.003
6MWT (m) 0.556 < 0.001common comorbidities were hypertension (96.5%) and
diabetes mellitus (24.1%). In the laboratory variables,
there were significant differences in serum levels of po-
tassium, alkaline phosphatase, PTH-i, haemoglobin, and
bicarbonate (Table 1). Only 1 patient presented albumin
levels of < 3.5 g/dL.
In this study, only 2 (6.8%) patients were anaemic, and
these were incidents in the clinic and they had not yet
reversed this condition, and used erythropoietin. About
37.9% of the patients used beta-blockers and all hyper-
tensive patients were using ACE inhibitors and/or angio-
tensin receptor blockers. Sodium bicarbonate, calcium
chelating and vitamin D agents were used where neces-
sary, in accordance with the guidelines of the Brazilian
Society of Nephrology [27,28].
There were no significant differences in spirometric
measures among groups. Among the manovacuometry
variables, PImax (%) differed between groups, but the
difference was not statistically significant (p = 0.06)
(Table 2).
In the CPET, VO2peak was lower in the G4 and G5
groups than in the CG (p = 0.03), while values of relative
power maximal (RPmax) (p < 0.01), oxygen consump-
tion at anaerobic threshold (VO2AT) (p < 0.01) and
maximum heart rate (HRmax) (p < 0.01) were lower in
the 3 CKD groups than in the control. Likewise, distance
walked in the 6MWT was lower in the G4 and G5
groups than in the CG (Table 3). Maximal exercise toler-
ance (VO2peak and RPmax) and submaximal exercise
tolerance (VO2AT and 6MWT), FEV1 and FCV were cor-
related with eGFR (Table 4 and Figure 2). The criteria for
discontinuation of CPET were the same as recommended
Figure 2 Correlations between estimated glomerular filtration rate and six-minute walk test (6MWT) and cardiopulmonary exercise
test (CPET).
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there were no complications; in addition, all tests were
stopped when the patients reached physical exhaustion.
The correlation between pulmonary function and exer-
cise tolerance was performed and a weak correlation be-
tween FVC (%) and VO2peak: r = 0.34 and p = 0.05; FVC
(%) and VO2peak (%): r = 0.37 and p = 0.03; and FEV1 (%)
and VO2peak (%): r = 0.37 and p = 0.03 were observed.
Discussion
In this study was observed that pre-dialytic CKD pa-
tients showed lower maximal and submaximal exercise
tolerances than healthy individuals. In addition, eGFR
was correlated with reduced exercise tolerance and pul-
monary function.
Most studies of respiratory function and exercise tol-
erance in CKD patients have included patients under-
going haemodialysis or peritoneal dialysis, treatments
that can interfere with pulmonary function [7,8]. The
few studies performed in pre-dialytic CKD patients
have not excluded factors that may contribute to re-
duced exercise tolerance and impaired pulmonary func-
tion, such as smoking [11] or were carried out with
children [29]. Because major confounders such as
aging, smoking, previous pulmonary disease and medi-
cations that can interfere with respiratory function were
excluded, this study was able to assess only the impact
of CKD and its associated changes in exercise tolerance
and lung function.
So far, few studies have been performed on exercise
tolerance in patients not yet on dialysis [15]. In CKD
patients, particularly those undergoing dialysis, reduced
exercise tolerance is associated with conditions such as
anaemia, sedentary lifestyle, decreased muscular strength
and resistance, and chronic inflammation [10,30-32].Exercise tolerance can be assessed by relatively complex
tests such as CPET or by simple low-cost tests such as
6MWT.
The incremental CPET quantifies VO2peak, which is
considered the gold standard for determining maximal
exercise tolerance. In a recent review, Johansen and
Painter [33] report a mean reduction of 50% - 80% of
VO2peak in pre-dialytic CKD patients. In this study,
VO2peak was also lower in pre-dialytic CKD patients
than in the CG and correlated with eGFR. Accordingly,
in a study published by Clyne et al. [15], the authors
showed in pre-dialytic CKD patients, that exercise
tolerance reduces with progress of kidney disease and
VO2peak of these patients is approximately 60% lower
than healthy controls. The CPET also offers important
information on submaximal exercise tolerance by deter-
mining metabolic responses at the AT, which permit an
assessment of the efficiency of aerobic metabolism. Dur-
ing activities performed below the AT, energy sources
are aerobic, and there is no sustained accumulation of
lactate. On the other hand, anaerobic glycolysis occurs
above this threshold, which results in the production
and accumulation of lactate [34]. In the present study,
reduced VO2AT, indicative of less efficient energy produc-
tion by aerobic mechanisms, was observed in patients
with lower eGFR. Clinically, the less efficient aerobic
mechanism leads to greater muscular fatigue and lower
exercise tolerance.
Submaximal exercise tolerance may also be quantified
by the 6MWT. This test is easy to perform, requires no
special equipment, is better tolerated by patients and is
more representative of daily activities than the incre-
mental CPET [24]. Some authors have reported lower
distances in 6MWT in CKD patients when compared
with healthy individuals [35-37]. In one such study, Cury
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with inefficiencies in the uptake, transport, and use of
O2 caused by dysfunction of cardiovascular, respiratory
and muscular systems.
In the present study, also was recorded shorter dis-
tances walked in the 6MWT by CKD patients and this
result was more evident in those with lowest eGFR.
Since the ventilatory response (minute ventilation) was
not altered during the CPET in CKD patients, the de-
creasing in exercise tolerance in these patients can be
associated with disturbance in cardiovascular system or
peripheral muscles. In addition, pulmonary function was
assessed by spirometry and showed no differences be-
tween groups, supporting the findings obtained in the
CPET. Moreover, there was only a weak correlation be-
tween pulmonary function and exercise tolerance.
The reduced exercise capacity in patients on haemodi-
alysis may be due to changes in transport mechanisms
and oxygen extraction. The transport of oxygen in these
patients may be altered by reduced cardiac output,
changes in maximum heart rate and decreased arterial
oxygen by anemia, while the impairment of oxygen ex-
traction may be due to uremic myopathy and disuse at-
rophy [38-40]. In this study, the hemoglobin level was
appropriate and not correlated with lung function and
CPET related variables.
CKD patients may present conditions that result in
ventilatory limitations, such as musculoskeletal weakness
[37,41,42], interstitial edema and edema of small airways
[13], pleural effusion [17] and osteoarticular changes in
the thoracic vertebrae [43]. In the present study, there
were no significant differences in spirometric test results
between CKD patients and the CG, but a positive correl-
ation between eGFR, FVC, and FEV1 was observed,
which suggests some decline in pulmonary function
associated with deteriorating kidney function. The rela-
tively small number of patients that was studied and the
small magnitude of the loss of pulmonary function may
explain the lack of statistically significant differences be-
tween groups in the spirometric data.
Decreased muscular strength may have multiple causes,
including reduced carnitine level, hypovitaminosis D,
hypotrophy of type-II muscle fibres, decreased energy use
by muscle fibres, increased PTH-i [29], metabolic acidosis,
chronic inflammation [44], decreases in oxidative metab-
olism, decreases in serum levels of calcium and increases
in protein catabolism [37]. In the present study, CKD pa-
tients showed a tendency of lower values of PImax (%)
than the CG (p = 0.06), in agreement with previous re-
ports that skeletal muscles, including the respiratory mus-
culature, presented lower strength and resistance over the
course of CKD [9,22]. It is also possible that changes to
other musculoskeletal groups, such as those in the lower
limbs, also contributed to decreased exercise tolerance.This study presented limitations. First, the fact that it
is a cross-sectional study limits the interpretation of the
impact of CKD on the observed results. Second, the ex-
clusion of possible factors known to decrease pulmonary
function limited the size of study sample. Third, these
results cannot be interpreted as broadly representative,
because the study was carried out in non-elderly patients
at a single centre. Finally, it is important to emphasize
that the patients who participated in this study were also
participating in a CKD secondary prevention programme,
received interdisciplinary treatment and were clinically
stable and under close observation.
Conclusion
The present study showed that pre-dialytic CKD patients
had a reduction in maximal and submaximal exercise
tolerances. In this context, CPET can be used for exercise
prescription before an inclusion in exercise programmes
which should be started early in the course of the disease.
Nevertheless, further studies are necessary to confirm
these outcomes.
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